Catalyst Pharmaceuticals Announces Participation in Key Scientific Conferences
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a dynamic biopharmaceutical entity devoted to developing innovative treatments for rare and challenging diseases, is gearing up for significant presentations at various scientific conferences where critical research and data will be showcased.
Commitment to Patient-Centric Research
At Catalyst, the priority is always the patients. Rich Daly, the President and CEO, emphasized this mission by stating that the company's presence at these conferences is a testament to its dedication to evolving therapies that substantially benefit those they serve. This dedication is fortified by robust clinical research collaborations, indicating a solid foundation for future advancements.
Highlights of Upcoming Conference Presentations
Child Neurology Society (CNS) Annual Meeting
One of the notable conferences is the Child Neurology Society Annual Meeting. During this event, Catalyst will present findings on the relationship between glucocorticoid treatment duration and healthcare resource utilization in patients with Duchenne Muscular Dystrophy. This real-world analysis is crucial, given the increasing need for effective treatment strategies.
American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)
Another significant event is the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting. Catalyst will participate in poster sessions, discussing the implications of glucocorticoid treatment on clinical outcomes in Duchenne Muscular Dystrophy. These insights will contribute to ongoing conversations regarding best practices in the management of this condition.
Myasthenia Gravis Foundation of America Scientific Session
The Myasthenia Gravis Foundation of America will also feature Catalyst's work. Presenting on patient characteristics and the timeline for achieving stable doses with amifampridine phosphate provides critical insights into treatment patterns for Lambert-Eaton Myasthenic Syndrome patients. This data sheds light on treatment effectiveness and patient experiences.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. is not just focused on medication development; it's about making a genuine difference in the lives of individuals affected by rare diseases. Known for its innovative solutions and steadfast commitment to patient accessibility, Catalyst sets the stage for comprehensive support systems aimed at ensuring patients have the necessary resources. This includes maintaining a prominent presence in the U.S. market while actively exploring opportunities for global expansion. Its headquarters are located in Coral Gables, Fla., where the company continues to be recognized for its strategic successes, including placements on notable industry lists.
For further information about Catalyst’s initiatives and ongoing projects, please visit www.catalystpharma.com.
Frequently Asked Questions
What is Catalyst Pharmaceuticals focusing on at these conferences?
Catalyst Pharmaceuticals is highlighting innovative research and data related to treatments for rare diseases, particularly Duchenne Muscular Dystrophy and Myasthenia Gravis.
Who is presenting at the Child Neurology Society Annual Meeting?
Steven D Woods, PharmD, will present data on glucocorticoid treatment duration and healthcare resource utilization in Duchenne Muscular Dystrophy.
What is the significance of the presentations at AANEM?
The presentations aim to share findings on glucocorticoid treatment effects on clinical outcomes, enhancing understanding of treatment protocols for Duchenne Muscular Dystrophy.
What is Catalyst's mission?
Catalyst Pharmaceuticals is dedicated to developing and providing access to therapies that improve the lives of patients with rare and difficult-to-treat diseases.
How can I contact Catalyst Pharmaceuticals for more information?
For inquiries, you may contact Melissa Kendis via email at IR@catalystpharma.com or reach out to David Schull at Russo Partners at (858) 717-2310.
